ORIN-1001 by Shanghai Fosun Pharmaceutical (Group) for Kidney Cancer (Renal Cell Cancer): Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ORIN-1001 overview

ORIN-1001 is under development for the treatment of advanced solid tumors including relapsed refractory triple-negative breast cancer, ER+ HER2- breast cancer, MYC+ breast cancer, hepatocellular carcinoma, prostate cancer, metastatic castration-resistant prostate cancer, pancreatic cancer, ovarian cancer, non-small cell lung cancer, esophageal cancer, idiopathic pulmonary fibrosis, human epidermal growth factor receptor 2 positive breast cancer (HER22+ breast cancer), colorectal cancer and kidney cancer (renal cell cancer). The drug candidate is a new chemical entity administered by oral route in the form of tablet. The drug candidate acts by targeting inositol requiring protein 1 (IRE1).

Shanghai Fosun Pharmaceutical (Group) overview

Shanghai Fosun Pharmaceutical (Group) (Fosun Pharma), a subsidiary of Shanghai Fosun High Technology (Group) Co Ltd, is a drug company that offers pharmaceutical products, medical diagnostic products and medical device products. The company’s pharmaceutical products are mainly applied in the treatment of metabolism and digestive system, cardiovascular system, blood system, central nervous system, anti-infection, anti-tumor, vaccine and raw material and intermediates. Fosun Pharma provides medical diagnostic products includes real time PCR detector, human papillomavirus assay kit, HBV quantitative reagent, and biofosun microorganism identification and susceptibility analysis system. The company’s research and development unit concentrates on therapeutic areas of metabolism and digestive system, blood system, cardiovascular system and central nervous system. Fosun Pharma is headquartered in Shanghai, China.

For a complete picture of ORIN-1001’s drug-specific PTSR and LoA scores, buy the report here.

Subscribe to our Newsletter

Get industry leading news, data and analysis delivered to your inbox

Subscribe

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.